Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Onyx’s Kyprolis Sails Through FDA Panel, Boosted By Confirmatory Trial Plans

This article was originally published in The Pink Sheet Daily

Executive Summary

The Oncologic Drugs Advisory Committee overwhelmingly concluded that carfilzomib has a positive risk/benefit assessment in relapsed/refractory myeloma. Onyx’s fully enrolled Phase III confirmatory trial, and the company’s plans for a second study that will commence soon, gave the committee confidence in recommending accelerated approval despite the limitations of a single-arm study.


Related Content

Onyx’s Myeloma Drug Kyprolis Fits ODAC’s View On Accelerated Approval
Counting The Cost Of Delay For Revlimid Front-line Myeloma Approval
Safety Concerns Weigh On Onyx’s Carfilzomib In Multiple Myeloma
Accelerated And Accompanied: Oncology Drugs Should Use Randomized Trials, FDA Panel Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts